未知生产厂商
Anthrax vaccine is a vaccine indicated for the pre- and post-exposure prophylaxis treatment of diseases caused by exposure to Bacillus anthracis
Anthrax vaccine is a vaccine indicated for the pre- and post-exposure prophylaxis treatment of diseases caused by exposure to Bacillus anthracis
The anthrax vaccine induces antibodies raised against PA that may contribute to protection by neutralizing the activities of the cytotoxic lethal toxin and edema toxin of Bacillus anthracis. Bacillus anthracis proteins other than PA may be present in BioThrax, but their contribution to protection has not been determined.
CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted) is a vaccine indicated for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis in persons 18 through 65 years of age when administered in conjunction with recommended antibacterial drugs. BioThrax is also approved for the same condition but is also used for pre-exposure prophylaxis for people whose occupation or other activities place them at high risk of exposure. The efficacy of CYFENDUS for post-exposure prophylaxis (PEP) is based solely on studies in animal models of inhalational anthrax.
共 1 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
